VV116 是一种针对呼吸道合胞病毒和 SARS-CoV-2 感染的选择性和口服活性核苷抗病毒剂。

VV116 is a selective and orally active nucleoside antiviral agent against respiratory syncytial virus (RSV) and SARS-CoV-2 infection.

VV116 (0-1000 μM) inhibited RSV replication in A549 cells with EC50 of 1.20 μM, CC50 of 95.92 μM and selectivity index (SI) of 80[2].

In Balb/c mice, VV116 (25, 50 and 100 mg/kg; p.o.) exhibits favorable PK properties and good safety profile. VV116 (25, 50 and 100 mg/kg; p.o.) exhibits a stronger activity and decreases the virus titers below the detection limit at 50 mg/kg, also reduces lung injury after RSV infection[2].

2647442-33-7

C24H30DN5O7

502.54

JT001

DMSO:245 mg/mL (419.92 mM),Need ultrasonic
Powder: -20°C for 3 years
In solvent: -80°C for 2 years